Literature DB >> 35242524

Sustained response to erythropoietin for anemia in NK-cell large granular lymphocytosis: A brief case report.

Tendai Kwaramba1, Brian Lewis2, Bruce Burks3, Bernardo Ruiz4, Swaminathan P Iyer5, Firas Safa2.   

Abstract

Large granular lymphocytic leukemia (LGL) is a rare lymphoproliferative disorder that involves the T-cell lineage in around 85% of cases and NK-cell lineage in 15%. Most patients require treatment at some point of their disease trajectory to address clinical symptomatology largely pertaining to cytopenia. While immunosuppression represents the backbone of LGL therapy, there is no consensus on the best next line following failure of immunosuppression. Here we present a case of LGL-associated cytopenia in a 73-year-old male refractory to immunosuppression, treated with adjunct erythropoietin alpha (EPO) with a marked response. Our case suggests that EPO therapy may provide therapeutic benefit in refractory LGL cases when used in conjunction with immunosuppressive therapy. Published by Elsevier Ltd.

Entities:  

Keywords:  Anemia; CLPD-NKs; EPO

Year:  2022        PMID: 35242524      PMCID: PMC8857583          DOI: 10.1016/j.lrr.2022.100292

Source DB:  PubMed          Journal:  Leuk Res Rep        ISSN: 2213-0489


  8 in total

1.  Anemia in Lymphoproliferative Disorders.

Authors: 
Journal:  Cancer Control       Date:  1998-03       Impact factor: 3.302

2.  Concurrent administration of darbepoetin alfa, cyclosporine A, and prednisolone is useful for T cell large granular lymphocyte leukemia associated with myelodysplastic syndrome complicated by Coombs-negative hemolytic anemia.

Authors:  Tetsumi Yoshida; Keichiro Mihara; Koji Arihiro; Tatsuji Mino; Hideki Asaoku; Tatsuo Ichinohe
Journal:  Ann Hematol       Date:  2014-04-23       Impact factor: 3.673

Review 3.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

4.  Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases.

Authors:  Benoît Bareau; Jérôme Rey; Mohamed Hamidou; Jean Donadieu; Jeff Morcet; Oumedaly Reman; Nicolas Schleinitz; Olivier Tournilhac; Mikael Roussel; Thierry Fest; Thierry Lamy
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

Review 5.  LGL leukemia: from pathogenesis to treatment.

Authors:  Thierry Lamy; Aline Moignet; Thomas P Loughran
Journal:  Blood       Date:  2017-01-23       Impact factor: 22.113

Review 6.  Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia.

Authors:  HeeJin Cheon; Karolina H Dziewulska; Katharine B Moosic; Kristine C Olson; Alejandro A Gru; David J Feith; Thomas P Loughran
Journal:  Curr Hematol Malig Rep       Date:  2020-04       Impact factor: 3.952

Review 7.  Anemia in malignancies: pathogenetic and diagnostic considerations.

Authors:  Balan Louis Gaspar; Prashant Sharma; Reena Das
Journal:  Hematology       Date:  2014-03-26       Impact factor: 2.269

8.  STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia.

Authors:  Andres Jerez; Michael J Clemente; Hideki Makishima; Hanna Koskela; Francis Leblanc; Kwok Peng Ng; Thomas Olson; Bartlomiej Przychodzen; Manuel Afable; Ines Gomez-Segui; Kathryn Guinta; Lisa Durkin; Eric D Hsi; Kathy McGraw; Dan Zhang; Marcin W Wlodarski; Kimmo Porkka; Mikkael A Sekeres; Alan List; Satu Mustjoki; Thomas P Loughran; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2012-08-02       Impact factor: 22.113

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.